| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Nigel Mackman | |
| Mark B Taubman | |||
| Raj S Kasthuri | |||
| P2860 | cites work | Role of tissue factor in hemostasis, thrombosis, and vascular development | Q28259220 |
| Alternatively spliced tissue factor - one cut too many? | Q28281583 | ||
| Regulation of the tissue factor gene | Q28293617 | ||
| Microvesicle-associated tissue factor and Trousseau's syndrome | Q29026182 | ||
| Thrombin signalling and protease-activated receptors | Q29619601 | ||
| Targeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostatic cancer | Q30453862 | ||
| Tissue factor-dependent coagulation is preferentially up-regulated within arterial branching areas in a baboon model of Escherichia coli sepsis | Q30477051 | ||
| Tissue factor pathway inhibitor reduces experimental lung metastasis of B16 melanoma | Q33342983 | ||
| Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation | Q33379387 | ||
| Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: effect on tumor initiation and angiogenesis | Q33710084 | ||
| Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration | Q33723243 | ||
| Contribution of host-derived tissue factor to tumor neovascularization | Q33765271 | ||
| Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer | Q33765406 | ||
| Role of tissue factor and protease-activated receptors in a mouse model of endotoxemia. | Q33815424 | ||
| Tissue factor is rapidly induced in arterial smooth muscle after balloon injury | Q33900126 | ||
| Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice | Q34186249 | ||
| Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis | Q34635642 | ||
| Intratumoral injection of adenoviral vectors encoding tumor-targeted immunoconjugates for cancer immunotherapy | Q35201112 | ||
| Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. | Q35763766 | ||
| Tissue factor expression during human and mouse development | Q35782371 | ||
| Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms | Q35850648 | ||
| Cancer and venous thromboembolism: scope of the problem | Q36265569 | ||
| Inhibition of tissue factor signaling suppresses tumor growth | Q36384586 | ||
| Sources of tissue factor | Q36396851 | ||
| Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model | Q36417960 | ||
| Procoagulant microparticles: disrupting the vascular homeostasis equation? | Q36600785 | ||
| Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer | Q36609724 | ||
| Regulation of tissue factor gene expression in the monocyte procoagulant response to endotoxin | Q36758072 | ||
| Protease-activated receptor (PAR) 2, but not PAR1, signaling promotes the development of mammary adenocarcinoma in polyoma middle T mice | Q37000605 | ||
| Blood-borne tissue factor: another view of thrombosis | Q37181879 | ||
| Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis | Q37341182 | ||
| Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasis | Q37380155 | ||
| Tissue factor expression by endothelial cells in sickle cell anemia | Q37381439 | ||
| Transcriptional regulation of tissue factor expression in human endothelial cells | Q38295839 | ||
| Chemotherapy-induced thrombin generation via procoagulant endothelial microparticles is independent of tissue factor activity | Q40070588 | ||
| Microparticle-associated tissue factor activity: a link between cancer and thrombosis? | Q40260694 | ||
| Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis | Q40502054 | ||
| Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis | Q40576775 | ||
| Expression of tissue factor, thrombomodulin, and E-selectin in baboons with lethal Escherichia coli sepsis | Q41992252 | ||
| Trousseau's syndrome associated with tissue factor produced by pulmonary adenocarcinoma | Q42772744 | ||
| Procoagulant activity associated with plasma membrane vesicles shed by cultured tumor cells. | Q44654420 | ||
| Role of tissue factor in embryonic blood vessel development. | Q45878003 | ||
| Chemotherapeutic agents doxorubicin and epirubicin induce a procoagulant phenotype on endothelial cells and blood monocytes | Q46136652 | ||
| A role for thrombin receptor signaling in endothelial cells during embryonic development | Q46345481 | ||
| In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy | Q46549052 | ||
| Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. | Q47866335 | ||
| Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. | Q52163110 | ||
| Association of tissue-factor upregulation in squamous-cell carcinoma of the lung with increased tissue factor in circulating blood. | Q52939282 | ||
| Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. | Q55039060 | ||
| Prognosis of Cancers Associated with Venous Thromboembolism | Q57301047 | ||
| Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature | Q60542083 | ||
| Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience | Q60651985 | ||
| Tissue factor expression in human leukocytes and tumor cells | Q64134913 | ||
| In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease | Q70934414 | ||
| Tissue factor expression correlates with histological grade in human pancreatic cancer | Q71991852 | ||
| Tissue factor expression in human colorectal carcinoma: correlation with hepatic metastasis and impact on prognosis | Q73368586 | ||
| Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant | Q73936936 | ||
| Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer | Q79478642 | ||
| Targeting patients for anticoagulant prophylaxis trials in patients with cancer: who is at highest risk? | Q79906628 | ||
| Tissue factor and PAR signaling in tumor progression | Q79906656 | ||
| Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer | Q80341297 | ||
| Tissue factor activity in whole blood | Q81157689 | ||
| P433 | issue | 29 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 4834-4838 | |
| P577 | publication date | 2009-09-08 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Role of tissue factor in cancer | |
| P478 | volume | 27 |
| Q42589106 | (111)Indium Labelling of Recombinant Activated Coagulation Factor VII: In Vitro and Preliminary In Vivo Studies in Healthy Rats |
| Q39506255 | 2-Methoxyestradiol inhibits progesterone-dependent tissue factor expression and activity in breast cancer cells |
| Q90587215 | 86/90Y-Labeled Monoclonal Antibody Targeting Tissue Factor for Pancreatic Cancer Theranostics |
| Q84511149 | A rare presentation of an uncommon malignancy: thromboembolism in a patient with a gastrointestinal stromal tumor |
| Q34167387 | A retrospective analysis of plasma D-dimer dynamic variation in terminal stage cancer patients: implications for disease progression |
| Q39396683 | Absence of tissue factor expression by neoplastic plasma cells in multiple myeloma |
| Q38496748 | Absence of tissue factor is characteristic of lymphoid malignancies of both T- and B-cell origin |
| Q64249468 | Activation of TF-Dependent Blood Coagulation Pathway and VEGF-A in Patients with Essential Thrombocythemia |
| Q36821572 | Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go? |
| Q38030018 | Adhesion receptors as therapeutic targets for circulating tumor cells |
| Q55504653 | Advances of tissue factor in lung cancer |
| Q44982133 | Advances on mechanisms of coagulation with non-small cell lung cancer |
| Q38616250 | Adverse Outcome Pathways for Regulatory Applications: Examination of Four Case Studies With Different Degrees of Completeness and Scientific Confidence. |
| Q37578965 | An expression signature at diagnosis to estimate prostate cancer patients' overall survival |
| Q64245835 | Analysis of the role of thrombomodulin in all-trans retinoic acid treatment of coagulation disorders in cancer patients |
| Q50088636 | Androgen receptor dampens tissue factor expression via NF-κB and EGR1. |
| Q39030222 | Antibody-drug conjugates and other nanomedicines: the frontier of gynaecological cancer treatment. |
| Q35987865 | Association between micro particle-tissue factor activity, factor VIII activity and recurrent VTE in patients with acute pulmonary embolism |
| Q50563557 | Binding of EGF1 domain peptide in coagulation factor VII with tissue factor and its implications for the triggering of coagulation. |
| Q30496573 | Binding of anti-GRP78 autoantibodies to cell surface GRP78 increases tissue factor procoagulant activity via the release of calcium from endoplasmic reticulum stores |
| Q38805415 | Biological basis of personalized anticoagulation in cancer: oncogene and oncomir networks as putative regulators of coagulopathy |
| Q98183397 | Biomarkers in cancer patients at risk for venous thromboembolism: data from the AVERT study |
| Q26865716 | Biomolecular markers of cancer-associated thromboembolism |
| Q55332820 | Bladder squamous cell cancer accompanied by Trousseau's syndrome: a case report. |
| Q34463432 | Brain neoplasms and coagulation-lessons from heterogeneity |
| Q36391554 | Cancer and coagulation |
| Q37393386 | Cancer, clots and consensus: new understanding of an old problem. |
| Q53766125 | Central retinal artery occlusion, an early sign of crizotinib resistance in an alk positive adenocarcinoma of lung: A rare case report. |
| Q64998171 | Chemotherapy induced changes to fibrin clots properties in lung cancer: is it favorable? |
| Q43549952 | Clinical and prognostic significance of coagulation assays in gastric cancer |
| Q38205701 | Clinical models and biochemical predictors of VTE in lung cancer |
| Q92421604 | Coagulation Factor Xa Promotes Solid Tumor Growth, Experimental Metastasis and Endothelial Cell Activation |
| Q38962343 | Coagulation and angiogenic gene expression profiles are defined by molecular subgroups of medulloblastoma: evidence for growth factor-thrombin cross-talk |
| Q38108356 | Coagulation and metastasis: what does the experimental literature tell us? |
| Q58569905 | Coagulation biomarkers and prediction of venous thromboembolism and survival in small cell lung cancer: A sub-study of RASTEN - A randomized trial with low molecular weight heparin |
| Q36853911 | Coexpression of heparanase activity, cathepsin L, tissue factor, tissue factor pathway inhibitor, and MMP-9 in proliferative diabetic retinopathy |
| Q36732743 | Colon Cancer Growth and Dissemination Relies upon Thrombin, Stromal PAR-1, and Fibrinogen |
| Q54728791 | Commentary on "microparticle-associated tissue factor activity in patients with metastatic pancreatic cancer and its effect on fibrin clot formation". |
| Q90392715 | D-dimer levels at diagnosis and long-term clinical outcomes in venous thromboembolism: from the COMMAND VTE Registry |
| Q42335804 | D-dimer measured at first venous thromboembolism is associated with future risk of cancer |
| Q39433444 | Defining MAP3 kinases required for MDA-MB-231 cell tumor growth and metastasis |
| Q33390865 | Dermatologic aspects of anticoagulation |
| Q92409584 | Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal Antibodies |
| Q99551846 | Down syndrome iPSC model: endothelial perspective on tumor development |
| Q92758073 | Down-regulation of tissue factor inhibits invasion and metastasis of non-small cell lung cancer |
| Q42385426 | Dual Targeting of Tissue Factor and CD105 for Preclinical PET Imaging of Pancreatic Cancer. |
| Q50047581 | Dynamic MR imaging for functional vascularization depends on tissue factor signaling in glioblastoma |
| Q42485431 | Effect of hypoxia on tissue factor pathway inhibitor expression in breast cancer |
| Q47174386 | Efficacy and safety of apatinib combined with transarterial chemoembolization for hepatocellular carcinoma with portal venous tumor thrombus: a retrospective study |
| Q34565533 | Elevated levels of plasma D-dimer predict a worse outcome in patients with nasopharyngeal carcinoma |
| Q40350703 | Elevated preoperative plasma D-dimer level is a useful predictor of chemoresistance and poor disease outcome for serous ovarian cancer patients |
| Q42553740 | Elevated pretreatment plasma D-dimer levels and platelet counts predict poor prognosis in pancreatic adenocarcinoma |
| Q39173889 | Endothelial cell protein C receptor opposes mesothelioma growth driven by tissue factor |
| Q51003877 | Evaluation of venous thrombosis and tissue factor in epithelial ovarian cancer. |
| Q39762177 | Expression of Tissue Factor in Epithelial Ovarian Carcinoma Is Involved in the Development of Venous Thromboembolism |
| Q58552509 | Expression of tissue factor in human cervical carcinoma tissue |
| Q61818351 | Extracellular vesicle-associated procoagulant phospholipid and tissue factor activity in multiple myeloma |
| Q40373557 | Factor VII deficiency impairs cutaneous wound healing in mice |
| Q50712955 | Factors Predicting Spontaneous Thrombosis of Aggressive Cranial Dural Arteriovenous Fistulas. |
| Q40425505 | Fibrinogen and D-dimer levels elevate in advanced hepatocellular carcinoma: High pretreatment fibrinogen levels predict poor outcomes |
| Q34078502 | Generation and characterisation of novel pancreatic adenocarcinoma xenograft models and corresponding primary cell lines |
| Q84340525 | Hemostatic factors, innate immunity and malignancy |
| Q36133005 | High D-dimer levels are associated with poor prognosis in cancer patients |
| Q35975572 | High Pretreatment D-Dimer Levels Correlate with Adverse Clinical Features and Predict Poor Survival in Patients with Natural Killer/T-Cell Lymphoma |
| Q37001337 | Hypoxia regulates the expression of tissue factor pathway signaling elements in a rat glioma model. |
| Q35164701 | Hypoxia triggers a proangiogenic pathway involving cancer cell microvesicles and PAR-2-mediated heparin-binding EGF signaling in endothelial cells. |
| Q45734083 | Idiopathic venous thromboembolism: a potential surrogate for occult cancer |
| Q36374066 | Immuno-PET of tissue factor in pancreatic cancer |
| Q46198687 | ImmunoPET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer with a Dual-Labeled Bispecific Antibody Fragment. |
| Q38607046 | ImmunoPET imaging of tissue factor expression in pancreatic cancer with 89Zr-Df-ALT-836. |
| Q54049063 | Increased thrombin generation in a mouse model of cancer cachexia is partially interleukin-6 dependent. |
| Q50629502 | Increased tissue factor expression is an independent predictor of mortality in clear cell carcinoma of the kidney. |
| Q37641624 | Inhibition of interleukin-1β-induced endothelial tissue factor expression by the synthetic cannabinoid WIN 55,212-2. |
| Q35664886 | Interrelationships of circulating tumor cells with metastasis and thrombosis: role of microRNAs |
| Q38123237 | Investigational anticoagulants for hematological conditions: a new generation of therapies. |
| Q39227575 | Involvement of PKCα activation in TF/VIIa/PAR2-induced proliferation, migration, and survival of colon cancer cell SW620. |
| Q47201370 | Long Term Low Molecular Weight Heparin Anticoagulant Therapy Modulates Thrombin Generation and D-dimer in Patients with Cancer and Venous Thromboembolism. |
| Q35055504 | MDA-9/syntenin is essential for factor VIIa-induced signaling, migration, and metastasis in melanoma cells |
| Q45338721 | Microparticle-associated tissue factor activity in patients with pancreatic cancer: correlation with clinicopathological features. |
| Q39626842 | Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. |
| Q37922118 | Microparticles: a critical component in the nexus between inflammation, immunity, and thrombosis |
| Q30393523 | Molecular Imaging of Pancreatic Cancer with Antibodies |
| Q60929964 | Near-infrared photoimmunotherapy of pancreatic cancer using an indocyanine green-labeled anti-tissue factor antibody |
| Q33691654 | Nitrophorin 2, a factor IX(a)-directed anticoagulant, inhibits arterial thrombosis without impairing haemostasis |
| Q40229105 | Occult cancer-related first venous thromboembolism is associated with an increased risk of recurrent venous thromboembolism |
| Q38214950 | Oncogenes and the coagulation system--forces that modulate dormant and aggressive states in cancer |
| Q41709078 | Pathological expression of tissue factor confers promising antitumor response to a novel therapeutic antibody SC1 in triple negative breast cancer and pancreatic adenocarcinoma |
| Q34599754 | Platelet polyphosphate: an endogenous activator of coagulation factor XII |
| Q61816605 | Predicting VTE in Cancer Patients: Candidate Biomarkers and Risk Assessment Models |
| Q85372013 | Preoperative D-dimers as an independent prognostic marker in cervical carcinoma |
| Q57300262 | Preoperative plasma D-dimer predicts 1-year survival in colorectal cancer patients with absence of venous thromboembolism (VTE): a prospective clinical cohort study |
| Q39587521 | Progesterone utilizes distinct membrane pools of tissue factor to increase coagulation and invasion and these effects are inhibited by TFPI. |
| Q41201318 | Prognostic Value of Plasma D-dimer in Patients with Resectable Esophageal Squamous Cell Carcinoma in China |
| Q41421740 | Prognostic value of routine laboratory variables in prediction of breast cancer recurrence |
| Q50990931 | Prognostic value of the D-dimer test in oesophageal cancer during the perioperative period. |
| Q41593075 | Prognostic values of tissue factor and its alternatively splice transcripts in human gastric cancer tissues |
| Q53033345 | Proposal of the Coagulation Score as a Predictor for Short-Term and Long-Term Outcomes of Patients with Resectable Gastric Cancer. |
| Q93045069 | Protease-activated receptor-2 accelerates intestinal tumor formation through activation of nuclear factor-κB signaling and tumor angiogenesis in ApcMin/+ mice |
| Q34450747 | Protease-activated receptors mediate crosstalk between coagulation and fibrinolysis |
| Q86875175 | Pulmonary embolism and stroke as the initial manifestation of advanced metastatic pancreatic adenocarcinoma |
| Q47177842 | Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: the RASTEN trial |
| Q38295867 | Regulation of fibrin-mediated tumor cell adhesion to the endothelium using anti-thrombin aptamer |
| Q38017362 | Risk assessment for cancer-associated thrombosis: what is the best approach? |
| Q37956590 | Risk assessment models for cancer-associated venous thromboembolism |
| Q38214965 | Risk factors for venous thromboembolism in cancer: novel findings from the Vienna Cancer and Thrombosis Study (CATS). |
| Q34795476 | Role of tissue factor in venous thrombosis. |
| Q90724393 | Roles of Coagulation Proteases and PARs (Protease-Activated Receptors) in Mouse Models of Inflammatory Diseases |
| Q53162784 | Sarcoma spreads primarily through the vascular system: are there biomarkers associated with vascular spread? |
| Q51042911 | Screening for occult malignancy with FDG-PET/CT in patients with unprovoked venous thromboembolism. |
| Q50323362 | Serum tissue factor as a biomarker for renal clear cell carcinoma |
| Q36889043 | Structure-Function Relationship of the Interaction between Tissue Factor and Factor VIIa. |
| Q36572132 | Sulfatase 2 promotes breast cancer progression through regulating some tumor-related factors |
| Q33588136 | Targeting tissue factor on tumour cells and angiogenic vascular endothelial cells by factor VII-targeted verteporfin photodynamic therapy for breast cancer in vitro and in vivo in mice |
| Q59335689 | The Platelet Response to Tissue Injury |
| Q53309226 | The changes of blood coagulation in surgical patients with lung cancer |
| Q37413162 | The critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity. |
| Q37394516 | The effect of perioperative immunonutrition on the phagocytic activity of blood platelets in advanced gastric cancer patients. |
| Q42872382 | The management of recurrent VTE in cancer patients receiving therapeutic anticoagulation: the use of dual anticoagulant therapy combined with an IVC filter |
| Q48218215 | The mechanisms how heparin affects the tumor cell induced VEGF and chemokine release from platelets to attenuate the early metastatic niche formation. |
| Q42049307 | The prognostic value of D-dimer levels in endometrial cancer patients treated with intensity-modulated radiation therapy |
| Q37088087 | The prothrombotic activity of cancer cells in the circulation |
| Q33625063 | The role of thromboprophylaxis in cancer patients: emerging data. |
| Q38209132 | The survival detriment of venous thromboembolism with epithelial ovarian cancer |
| Q27014616 | The wound healing, chronic fibrosis, and cancer progression triad |
| Q37852747 | Therapeutic modulation of coagulation and fibrinolysis in acute lung injury and the acute respiratory distress syndrome |
| Q42248974 | Thrombin generation assay and transmission electron microscopy: a useful combination to study tissue factor-bearing microvesicles |
| Q33959220 | Thrombin regulates the metastatic potential of human rhabdomyosarcoma cells: distinct role of PAR1 and PAR3 signaling |
| Q37863640 | Thrombophilic state in cancer, part I: biology, incidence, and risk factors |
| Q56339353 | Thrombosis and cancer |
| Q91465884 | Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial |
| Q39927698 | Tissue Factor Pathway Inhibitor Gene Polymorphism -33T → C Predicts Improved Disease-Free Survival in Colorectal Cancer |
| Q34599765 | Tissue factor and tissue factor pathway inhibitor as key regulators of global hemostasis: measurement of their levels in coagulation assays |
| Q36565603 | Tissue factor as a novel target for treatment of breast cancer |
| Q36375642 | Tissue factor is strongly expressed in pericarcinomatous tissue in patients with laryngeal carcinoma |
| Q55442800 | Tissue factor-specific ultra-bright SERRS nanostars for Raman detection of pulmonary micrometastases. |
| Q39444496 | Tissue factor/activated factor VIIa induces matrix metalloproteinase-7 expression through activation of c-Fos via ERK1/2 and p38 MAPK signaling pathways in human colon cancer cell |
| Q34172935 | Tissue factor–dependent procoagulant activity of subtilase cytotoxin, a potent AB5 toxin produced by shiga toxigenic Escherichia coli |
| Q33795243 | Trousseau's Syndrome Caused by Intrahepatic Cholangiocarcinoma: An Autopsy Case Report and Literature Review |
| Q37169096 | Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients |
| Q33710071 | Tumors, ticks and tissue factor |
| Q39441349 | Undercover Agents: Targeting Tumours with Modified Platelets |
| Q95424345 | Unprovoked venous thromboembolism: assess for cancer |
| Q35005521 | Upregulation of tissue factor by activated Stat3 contributes to malignant pleural effusion generation via enhancing tumor metastasis and vascular permeability in lung adenocarcinoma |
| Q45126293 | Using annexin V-coated magnetic beads to capture active tissue factor-bearing microparticles from body fluids |
| Q38138289 | Venous thromboembolism during primary treatment of ovarian clear cell carcinoma is associated with decreased survival |
| Q38751462 | Venous thromboembolism in cancer patients: risk assessment, prevention and management |
Search more.